期刊文献+

缬沙坦治疗早期糖尿病肾病的临床观察 被引量:6

Clinical observation of angiotensin Ⅱ receptor antagonist on the treatment of earlier period of diabetes and kidney disease
原文传递
导出
摘要 目的观察血管紧张素Ⅱ受体拮抗剂缬沙坦应用对减少早期糖尿病肾病微量白蛋白尿的作用。方法36例早期糖尿病肾病患者使用缬沙坦80~160mg,每日1次,治疗8周,比较治疗前后血压、尿白蛋白量,并观察空腹血糖、糖化血红蛋白、甘油三酯、总胆固醇、内生肌酐清除率等变化。结果治疗后尿自蛋白明显下降(P〈0.01),而血压、空腹血糖、糖化血红蛋白、甘油三酯、总胆固醇、内生肌酐清除率无明显变化;治疗过程无明显不良反应。结论缬沙坦可减少尿白蛋白量,是治疗早期糖尿病肾病的有效药物之一。 Objective To observe the application of angiotensin Ⅱ receptor antagonist valsartan in reducing minim albuminuria in earlier period of the diabetes and kidney disease. Methods 36 patients who administered angiotensin Ⅱ receptor antagonist valsartan 80 - 160mg,qd, for 8 weeks. Compared with symptoms before the treatment,the blood pressure, the amount of the urinary albuminuria, and observed the change of the empty stomach blood sugar, the saccharified hemoglobin, the triglyceride, the total cholesterol, the endogenous creatinine clearance rate, etc. Results After the treatment, the urinary albumin drops obviously(P 〈 0.01 ), while the blood pressure, the empty stomach blood sugar, the saccharified hemoglobin, the triglyceride, the total cholesterol and the endogenous creatinine clearance rate have no obvious change. There is no obvious side effect during therapeutic process. Conclusion The application of angiotensin Ⅱ receptor antagonist valsartan can reduce the amount of the urinary albumin, is the effective way in treating the earlier period of the diabetes and kidney disease.
出处 《中国基层医药》 CAS 2008年第8期1282-1283,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 糖尿病肾病 受体 血管紧张素 临床分析 Diabetic nephropathies Receptors, angiotensin
  • 相关文献

参考文献4

二级参考文献13

  • 1武铁峰,王春田,马会利,刘晓波.缬沙坦治疗高血压性蛋白尿的疗效观察[J].中国综合临床,2004,20(8):706-707. 被引量:4
  • 2张小松,张新利.高血压诊断和治疗的新观点[J].中国基层医药,2004,11(8):1011-1012. 被引量:4
  • 3张九斌.N-乙酰-B-D氨基葡萄糖苷酶测定及临床意义[J].现代检验医学进展,2001,12(1):48.
  • 4王继贵.在糖尿病诊断和治疗中用于实验分析的指南和推荐CⅢ[J].华东临床检验信息,2002,1(4):122-123.
  • 5Rutkowski B,Tylicki L,Lysiak-Szydlowska W.Hypertensive nephropathy an increasing clinical probl.Miner Electrolyte Metab,1999,25(6):65-68.
  • 6戚仁锋,王淑娟,许国植等主编.诊断学.第3版.北京:人民卫生出版社,1992:366-367.
  • 7Goldberg MR,De Mey C,Wroblewski JM.et al.Differential effects of oral iosartan and enalapril on local venous and systemic pressor responses to angiotenain Ⅰand Ⅱ in healthy men.Clin Pharmacol Ther,1996,59(2):72-74.
  • 8Weber MA,Byyny RL,Pratt J H,et al.Blood pressure effects of the angiotensin Ⅱ receptor blocker.Iosartan West J Med,1998,168(3):272-273.
  • 9Goldberg AI,Dunlay MC,Sweet CS.Safety and tolerability of losartan compared with atenolol,felodipine and angiotensin coverting enzyme inhibitors.Hypertens,1995,13 (Supple 1):77-80.
  • 10Chan JC,Critchley JA,Lappe JT,et al.Randomised,double-blind,parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine Erin elderly patients with mild to moderate hypertension.Hum Hypertens,1995,9 (1):765-766.

共引文献35

同被引文献72

引证文献6

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部